341 results on '"Purtill, Duncan"'
Search Results
2. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update
3. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
4. International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced
5. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee
6. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond
7. Bariatric surgery and allogeneic hematopoietic stem cell transplantation: a case series
8. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis
9. The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee
10. Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study
11. Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
12. Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
13. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
14. The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR
15. Outcomes of Allogeneic Haematopoietic Transplant for Chronic Lymphocytic Leukaemia in the Modern Era
16. Bridging therapy before axi-cel for lymphoma
17. Survey of Infection Surveillance, Prophylaxis, and Vaccination Practices after Autologous Genetically Modified Cellular Therapies
18. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant
19. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial
20. Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry
21. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation
22. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond
23. ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease
24. High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission
25. Early cessation of a randomised study in acute graft versus host disease: upfront mesenchymal stromal cells with corticosteroids versus corticosteroids alone
26. COVID‐19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy.
27. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
28. OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy
29. P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL
30. Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic Malignancy
31. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant
32. Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
33. Killer Cell Immunoglobulin-Like Receptor–Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia
34. Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies
35. Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation
36. Continuous and Differential Improvement in Worldwide Access to Hematopoietic Cell Transplantation: Notable Increase of HCT for Non-Malignant Indications and from Non-Identical Related Donors
37. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering
38. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell
39. Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience
40. Learning from the bone allograft tuberculosis outbreak in the USA
41. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice
42. Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
43. Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies
44. Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment
45. Fitness criteria for Australian patients referred for chimeric antigen receptor T‐cell therapy
46. MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
47. MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
48. Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
49. Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
50. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.